ClinicalTrials.gg
CompletedNCT02598193Updated Jun 13, 2018Results posted

Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 4 interventional study of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 38 sites in 8 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
6th of 16
89 · median 49
Started
2016
with 2 others
Phase 4
5 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
1 of 16
Hoffmann-La Roche

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 6th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 4, and was the 5th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF. Eligible participants must have received pirfenidone for at least 16 weeks on a stable dose. Nintedanib will be added on Day 1 of the study as a combination treatment for IPF for 24 weeks.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are on pirfenidone for at least 16 weeks and on a stable dose (defined as 1602-2403 mg/day) for at least 28 days at the start of Screening; the dose must be expected to remain in that range throughout the study
  • Documented diagnosis of IPF, per the Investigator per using the criteria of the 2011 American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Association guidelines
  • Participants with percent predicted forced vital capacity (FVC) more than or equal to (>=) 50 percent (%) and percent predicted carbon monoxide diffusing capacity (DLco) >=30% at Screening
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of , including at least one method with a failure rate of less than (\<) 1% per year, during the treatment period and for at least 3 months after the final Follow-up Visit
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm during the treatment period and for at least 4 months after the final Follow-up Visit

Exclusion criteria

Exclusion Criteria:

  • Participants with clinical evidence of active infection
  • Participant with any new or ongoing moderate or severe adverse reaction considered by the Investigator to be related to pirfenidone, or an pirfenidone treatment interruption in the 28 days before the start of Screening
  • Any condition that is likely to result in death in the 12 months after the start of Screening
  • Lung transplantation anticipated or any planned significant surgical intervention
  • Known to the active substance or any of either pirfenidone or nintedanib
  • Mild ( A), moderate (Child Pugh B), or severe (Child Pugh C) hepatic and/or severe renal impairment
  • History of gastrointestinal (GI) tract perforation, unstable or deteriorating cardiac or pulmonary disease (other than IPF), long syndrome, alcohol or substance abuse in the 2 years before the start of screening, use of any tobacco product in the 12 weeks before the start of screening
  • Bleeding risk
  • Use of Cytochrome P450 (CYP) 1A2 (CYP1A2) inhibitors (for example, fluvoxamine, enoxacin) and/or use of inhibitors of P-glycoprotein (for example, ketoconazole, erythromycin) or (for example, ketoconazole, erythromycin) or their inducers (for example, rifampicin, carbamazepine, phenytoin, St John's wort) in the 28 days before the start of Screening
  • Pregnancy or lactation
  • Hypersensitivity to peanuts and/or soy
  • Use of pirfenidone and/or nintedanib in a clinical study protocol in the 28 days before the start of screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Pirfenidone+Nintedanib

    Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.

    Drug: Nintedanib · Drug: Pirfenidone

Interventions

  • Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.

    Also known as: Ofev

  • Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.

    Also known as: Esbriet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With Adverse Events and Serious Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline up to Week 28

  2. Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit

    Time frame: Baseline up to Week 24

  3. Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib

    Time frame: Baseline up to Week 24

  4. Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments

    Time frame: Baseline up to Week 24

07

Results

Posted Jun 13, 2018

Participant flow

Participants with idiopathic pulmonary fibrosis were recruited for this study.

Participant flow — Overall Study
MilestonePirfenidone+Nintedanib
Started89
Completed73
Not completed16
Withdrew: Adverse event13
Withdrew: Withdrawal by subject1
Withdrew: Listed in active lung transplant list1
Withdrew: Does not want to take nintedanib1

Outcome measures

PrimaryPercentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day
Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day
Percentage of ParticipantsPirfenidone+Nintedanib
Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day77.5 (67.4 to 85.7)
SecondaryPercentage of Participants With Adverse Events and Serious Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline up to Week 28
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events and Serious Adverse Events
Percentage of ParticipantsPirfenidone+Nintedanib
Adverse Event98.9
Serious Adverse Event18.0
SecondaryPercentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit
Time frame:
Baseline up to Week 24
Reported as:
Number · Percentage of Praticipants
Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit
Percentage of PraticipantsPirfenidone+Nintedanib
Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit14.6 (8.0 to 23.7)
SecondaryTotal Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib
Time frame:
Baseline up to Week 24
Reported as:
Number · Participant Days
Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib
Participant DaysPirfenidone+Nintedanib
Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib13330
SecondaryTotal Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments
Time frame:
Baseline up to Week 24
Reported as:
Mean · Number of Days
Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments
Number of DaysPirfenidone+Nintedanib
Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments149.8 ± 43.93

Adverse events

Collected over Baseline up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone+Nintedanib0/89 (0%)16/89 (18%)83/89 (93.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPirfenidone+Nintedanib
PneumothoraxRespiratory, thoracic and mediastinal disorders3/89
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders2/89
PneumomediastinumRespiratory, thoracic and mediastinal disorders1/89
Cholecystitis infectiveInfections and infestations1/89
InfluenzaInfections and infestations1/89
PneumoniaInfections and infestations1/89
TracheobronchitisInfections and infestations1/89
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/89
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/89
PancreatitisGastrointestinal disorders1/89
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPirfenidone+Nintedanib
DiarrhoeaGastrointestinal disorders52/89
NauseaGastrointestinal disorders44/89
VomitingGastrointestinal disorders29/89
CoughRespiratory, thoracic and mediastinal disorders20/89
FatigueGeneral disorders14/89
Decreased appetiteMetabolism and nutrition disorders14/89
HeadacheNervous system disorders13/89
DyspnoeaRespiratory, thoracic and mediastinal disorders10/89
DizzinessNervous system disorders9/89
Viral upper respiratory tract infectionInfections and infestations9/89

Baseline characteristics

Safety population included all participants who had received at least one dose of investigational medicinal product on or after Day 1.

Age, Continuous
Age, Continuous(Years)Pirfenidone+Nintedanib
Mean68.2 ± 6.82
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone+Nintedanib
Female18
Male71
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pirfenidone+Nintedanib
Hispanic or Latino9
Not Hispanic or Latino74
Unknown or Not Reported6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pirfenidone+Nintedanib
White84
Black or African American3
Asian1
Asian/White1
08

Study locations

38 sites
  • David Geffen School of Medicine at UCLA;Division of Pulmonary & Critical Care/ Department of Medic
    Los Angeles, California 90095-1690, United States
  • Stanford University School of Medicine ; Pulmonary/Critical Care Medicine
    Stanford, California 94305, United States
  • Sarasota Memorial Hospital
    Sarasota, Florida 34239, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109-0666, United States
  • Cardio-Pulmonary Associates of St. Luke's Hospital
    Chesterfield, Missouri 63017, United States
  • Creighton University
    Omaha, Nebraska 68131, United States
  • Atlantic Respiratory Institute
    Summit, New Jersey 07901, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Pulmonix LLC
    Greensboro, North Carolina 27403, United States
  • UC Health Clinical Trials Office
    Cincinnati, Ohio 45267, United States
  • John A. Butler, M.D. - Oregon Pulmonary Associates
    Portland, Oregon 97225, United States
  • Medical University of South Carolina (MUSC); MUSC Pulmonary
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Inova Health Care Services; Advanced Lung Disease Transplant Program
    Falls Church, Virginia 22042, United States
  • South Health Campus/Alberta Health Services/ University of Calgary
    Calgary, Alberta T3M 1M4, Canada
  • University Health Network
    Toronto, Ontario M5G 2N2, Canada
  • Gentofte Hospital, Lungemedicinsk Afdeling
    Hellerup, 2900, Denmark
  • Hopital Avicenne; Pneumologie
    Bobigny, 93000, France
  • Hopital Louis Pradel; Pneumologie
    Bron, 69677, France
  • Hopital de Pontchaillou; Service de Pneumologie
    Rennes, 35033, France
  • Fachkrankenhaus Coswig GmbH Zentrum f.Pneumologie Beatmungsmedizin Thorax-u.Gefäßchirurgie
    Coswig, 01640, Germany
  • Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie
    Essen, 45239, Germany
  • Klinikum Fulda gAG; Universitätsmedizin Marburg, Campus Fulda
    Fulda, 36043, Germany
  • ASST DI MONZA; U O Clinica Pneumologica
    Monza, Lombardia 20900, Italy
  • A.O. Universitaria San Luigi Gonzaga di Orbassano; Malattie Apparato Respiratorio (MAR2)
    Orbassano, Piemonte 10043, Italy
  • Azienda Ospedaliero Universitaria Pisana; U.O. Pneumologia
    Pisa, Toscana 56124, Italy
  • A.O. Univ. Senese Policlinico S. Maria alle Scotte; UOC Malattie Resepiratorie e Trapianto Polmonare
    Siena, Toscana 53100, Italy
  • Antonius Ziekenhuis; Dept of Lung Diseases
    Nieuwegein, 3435 CM, Netherlands
  • Erasmus MC; Afdeling Longziekten
    Rotterdam, 3000 CA, Netherlands
  • Hospital Universitari de Bellvitge ; Servicio de Neumologia
    Hospitalet de Llobregat, Barcelona 08097, Spain
  • Hospital del Henares; Medicina Interna. Unidad de Neumología
    Coslada (Madrid), Madrid 28822, Spain
  • Hospital Universitario de Canarias; Servicio de Neumologia
    La Laguna, Tenerife 38320, Spain
  • Complejo Asistencial Universitario de Leon; Pneumology
    Leon, 24071, Spain
  • Hospital Universitario La Princesa; Servicio de Neumologia
    Madrid, 28006, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Neumologia
    Sevilla, 41013, Spain
  • Hospital General Universitario De Valencia; Servicio de Neumologia
    Valencia, 46014, Spain
09

References and documents

Publications

  • Flaherty KR, Fell CD, Huggins JT, Nunes H, Sussman R, Valenzuela C, Petzinger U, Stauffer JL, Gilberg F, Bengus M, Wijsenbeek M. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J. 2018 Aug 2;52(2):1800230. doi: 10.1183/13993003.00230-2018. Print 2018 Aug. Erratum In: Eur Respir J. 2018 Oct 4;52(4):1850230. doi: 10.1183/13993003.50230-2018. PubMed 29946005 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in May 2017, 16 months.

Results were first posted in Jun 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2015
First posted
Nov 5, 2015
StartActual
Jan 14, 2016
Primary completionActual
May 16, 2017
CompletionActual
May 16, 2017
Results first posted
Jun 13, 2018
Last update
Jun 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02598193
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 5, 2015
Start date
Jan 14, 2016
Primary completion
May 16, 2017
Completion
May 16, 2017
Results posted
Jun 13, 2018
Last update
Jun 13, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Pirfenidone

Start the discussion